BRPI9912227A - método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método. - Google Patents

método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.

Info

Publication number
BRPI9912227A
BRPI9912227A BRPI9912227A BRPI9912227A BRPI9912227A BR PI9912227 A BRPI9912227 A BR PI9912227A BR PI9912227 A BRPI9912227 A BR PI9912227A BR PI9912227 A BRPI9912227 A BR PI9912227A BR PI9912227 A BRPI9912227 A BR PI9912227A
Authority
BR
Brazil
Prior art keywords
early
carcinomas
kit
carrying
vitro diagnosis
Prior art date
Application number
BRPI9912227A
Other languages
English (en)
Inventor
Knebel Doeberitz Magnus Von
Dimitri Spitkovsky
Original Assignee
Knebel Doeberitz Magnus Von
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knebel Doeberitz Magnus Von, Deutsches Krebsforsch filed Critical Knebel Doeberitz Magnus Von
Publication of BRPI9912227A publication Critical patent/BRPI9912227A/pt
Publication of BRPI9912227B1 publication Critical patent/BRPI9912227B1/pt
Publication of BRPI9912227B8 publication Critical patent/BRPI9912227B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

''método para diagnose precoce de carcinomas e kit para executar o mesmo''. a presente invenção relaciona-se a um método para diagnose precoce de carcinomas e os precursores do mesmo, compreendendo a determinação da manifestação excessiva de proteína reguladora de ciclo celular em uma amostra orgânica. a invenção também relaciona-se com um kit que pode ser usado par o citado método.
BRPI9912227 1998-07-01 1999-07-01 método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método. BRPI9912227B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19829473A DE19829473C2 (de) 1998-07-01 1998-07-01 Verfahren zur frühen Diagnose von Carcinomen
PCT/DE1999/002094 WO2000001845A2 (de) 1998-07-01 1999-07-01 Verfahren zur frühen diagnose von carcinomen

Publications (3)

Publication Number Publication Date
BRPI9912227A true BRPI9912227A (pt) 2001-04-24
BRPI9912227B1 BRPI9912227B1 (pt) 2013-08-20
BRPI9912227B8 BRPI9912227B8 (pt) 2021-07-06

Family

ID=7872684

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912227 BRPI9912227B8 (pt) 1998-07-01 1999-07-01 método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.

Country Status (22)

Country Link
US (2) US6709832B1 (pt)
EP (1) EP1092155B1 (pt)
JP (1) JP3404020B2 (pt)
KR (1) KR100646193B1 (pt)
CN (1) CN1209627C (pt)
AT (1) ATE230487T1 (pt)
AU (1) AU749769B2 (pt)
BR (1) BRPI9912227B8 (pt)
CA (1) CA2336153C (pt)
CZ (1) CZ292076B6 (pt)
DE (2) DE19829473C2 (pt)
DK (1) DK1092155T3 (pt)
ES (1) ES2190820T3 (pt)
HU (1) HUP0102744A2 (pt)
IL (1) IL140550A (pt)
MX (1) MXPA00012852A (pt)
NO (1) NO328685B1 (pt)
PL (1) PL198623B1 (pt)
RU (1) RU2217761C2 (pt)
SK (1) SK284056B6 (pt)
TR (1) TR200003903T2 (pt)
WO (1) WO2000001845A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
DE10006033B4 (de) * 2000-02-10 2005-11-10 Professor Dr. Magnus von Knebel Doeberitz Chirurgische Universitätsklinik Sektion für Molekulare Diagnostik und Therapie Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
JP4384852B2 (ja) * 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
EP1369694A1 (en) * 2002-04-09 2003-12-10 MTM Laboratories AG Method for discrimination of metaplasias from neoplastic or preneoplastic lesions
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
EP1600513B1 (en) * 2003-02-26 2010-02-24 Sysmex Corporation Method of examining a cell
ATE289685T1 (de) * 2003-08-25 2005-03-15 Mtm Lab Ag Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
ES2381644T3 (es) * 2004-03-24 2012-05-30 Tripath Imaging, Inc. Métodos y composiciones para la detección de enfermedades de cuello uterino
DE602005024964D1 (de) * 2004-05-31 2011-01-05 Sysmex Corp Verfahren zur beurteilung der malignität einer säuger-krebszelle
EP1628135A1 (en) * 2004-08-20 2006-02-22 MTM Laboratories AG Method for detecting medically relevant conditions in a solubilized LBC sample
US7892750B1 (en) * 2004-12-23 2011-02-22 University Of Notre Dame Du Lac Cathepsin E as a marker of colon cancer
JP4766969B2 (ja) 2005-09-14 2011-09-07 シスメックス株式会社 組織性質判定装置
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
SG10201400426XA (en) 2006-01-12 2014-07-30 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
WO2010129821A1 (en) * 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
JP5111902B2 (ja) * 2007-03-14 2013-01-09 シスメックス株式会社 癌の診断支援装置
EP2028600B1 (en) 2007-08-24 2016-10-26 Sysmex Corporation Diagnosis support system for cancer, diagnosis support for information providing method for cancer, and computer program product
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
US8900813B2 (en) 2010-08-17 2014-12-02 Medical Diagnostic Laboratories, Llc CIP2A as a biomarker in detection of cervical cancer
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
US9551700B2 (en) 2010-12-20 2017-01-24 Milagen, Inc. Device and methods for the detection of cervical disease
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
EP2773390B1 (en) 2011-11-03 2020-12-30 Tripath Imaging, Inc. Methods and compositions for preparing samples for immunostaining
AU2012340441A1 (en) * 2011-11-15 2014-05-29 University Of Miami Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
WO2019234176A1 (en) 2018-06-07 2019-12-12 Universitaet Des Saarlandes Novel biomarkers for carcinoma diagnosis
CN108893534A (zh) * 2018-06-26 2018-11-27 华中科技大学鄂州工业技术研究院 泛癌症诊断标记物
RU2707884C1 (ru) * 2018-10-03 2019-12-02 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ ранней диагностики почечно-клеточной карциномы по наличию антител к зрительному аррестину
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
CN111257565A (zh) * 2018-12-03 2020-06-09 上海细胞治疗集团有限公司 一种衰老细胞的检测试剂盒及其检测方法
CN113295683A (zh) * 2021-05-24 2021-08-24 烟台海关技术中心 过氧化苯甲酰检测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5268463A (en) * 1986-11-11 1993-12-07 Jefferson Richard A Plant promoter α-glucuronidase gene construct
PT665886E (pt) 1992-10-16 2003-10-31 Cold Spring Harbor Lab Rearranjo de complexos de ciclina e suas utilizacoes
WO1994012881A2 (en) * 1992-12-02 1994-06-09 Hochstrasser Denis F A METHOD FOR DETECTING GROWING CELLS USING TRANSLATIONALLY CONTROLLED TUMOR PROTEIN p21
US5543291A (en) * 1993-01-29 1996-08-06 Dana Farber Cancer Institute Method of detecting carcinoma
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
RU2164419C2 (ru) * 1994-03-18 2001-03-27 Мириад Дженетикс, Инк. Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts
CA2162150C (en) * 1994-03-18 2010-03-30 Mark H. Skolnick Germline mutations in the mts gene and method for detecting predisposition to cancer at the mts gene
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
US5976799A (en) 1996-03-21 1999-11-02 The Board Of Trustees Of The University Of Arkansas Early detection of ovarian carcinoma using P16 gene products
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
WO2000024245A1 (en) * 1998-10-28 2000-05-04 President And Fellows Of Harvard College REGULATION OF TH2 CELL ACTIVITY BY MODULATION OF NFATp AND NFAT4 ACTIVITY

Also Published As

Publication number Publication date
BRPI9912227B8 (pt) 2021-07-06
KR20010074632A (ko) 2001-08-04
SK20312000A3 (sk) 2001-10-08
RU2217761C2 (ru) 2003-11-27
US6709832B1 (en) 2004-03-23
PL345407A1 (en) 2001-12-17
JP2002519681A (ja) 2002-07-02
IL140550A (en) 2005-08-31
HUP0102744A2 (hu) 2001-11-28
CA2336153C (en) 2005-12-20
PL198623B1 (pl) 2008-07-31
CZ20004922A3 (cs) 2001-07-11
AU749769B2 (en) 2002-07-04
ATE230487T1 (de) 2003-01-15
US20030152993A1 (en) 2003-08-14
EP1092155B1 (de) 2003-01-02
DE59903915D1 (de) 2003-02-06
CZ292076B6 (cs) 2003-07-16
DK1092155T3 (da) 2003-03-24
JP3404020B2 (ja) 2003-05-06
CN1307681A (zh) 2001-08-08
EP1092155A2 (de) 2001-04-18
SK284056B6 (sk) 2004-08-03
WO2000001845B1 (de) 2000-04-20
NO328685B1 (no) 2010-04-26
NO20006681D0 (no) 2000-12-28
ES2190820T3 (es) 2003-08-16
DE19829473A1 (de) 2000-01-13
NO20006681L (no) 2001-02-26
BRPI9912227B1 (pt) 2013-08-20
CA2336153A1 (en) 2000-01-13
IL140550A0 (en) 2002-02-10
HK1038609A1 (zh) 2002-03-22
DE19829473C2 (de) 2000-08-10
AU5848799A (en) 2000-01-24
CN1209627C (zh) 2005-07-06
TR200003903T2 (tr) 2001-06-21
WO2000001845A3 (de) 2000-02-17
MXPA00012852A (es) 2003-09-11
WO2000001845A2 (de) 2000-01-13
KR100646193B1 (ko) 2006-11-17

Similar Documents

Publication Publication Date Title
BRPI9912227A (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
DK0925073T3 (da) Staphylococcus aureus antigen
DE60030274D1 (de) Aus ganzen zellen bestehender impfstoff, der staphylococcus aureus antigen enthält
SE7607173L (sv) Kromogent respektive fluorescerande substrat
ATE238557T1 (de) Krebsbehandlung
ES2160716T3 (es) Procedimiento para estabilizar la respuesta de un biosensor.
BR0006861A (pt) Processo de possibilitar que uma primeira rede doméstica de uma primeira arquitetura de software interaja com uma segunda rede doméstica de uma segunda arquitetura de software, sistema de processamento de informações, e, componente de software para uso em um sistema de ambiente doméstico
BR0009157B1 (pt) Conjugado antígeno transportador compreendendo um antígeno isolado de S. epidermidis, S. haemolyticus ou S. hominis
SE7906148L (sv) Forfarande for framstellning av en biologisk komposition for anvendning sasom referenskontroll vid diagnostiska tester
BR9907161A (pt) Uso de um ensaio quanto à adenilato quinase em um teste in vitro, processos para determinar a suscetibilidade de uma bactéria a um reagente, para determinar a sensibilidade de uma bactéria a um antibiótico ou agente bioestático, para determinar a fase de cultivo de uma cultura bacteriana , e, kit de teste para analisar a sensibilidade de bactérias a antibióticos
BR9607854A (pt) Processos para a medição da taxa de degradação de uma proteína do corpo e para obtenção de informação referente à degradação de proteína em um paciente utilização de um isômero sintético de um peptídeo e de um anticorpo anticorpo capa de células análogo de peptídeo sintético e kit de análise para utilização em um processo de análise
BR9800254A (pt) Reagente de coloração para a determinação de células sanguíneas
NO920852L (no) Midler for diagnostisering av demyelinisante neuropatier,saerlig multippel sklerose
NO331018B1 (no) In vitro fremgangsmate ved bestemmelse av pre-neoplastiske og/eller neoplastiske tilstander hos pattedyr ved purinergisk reseptorekspresjon, samt anvendelse og sett for slik pavisning
BR0115689A (pt) Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
ES2191111T3 (es) Procedimiento de produccion de una bebida alcoholica por fermentacion y kit de prueba de fermentacion usado en el procedimiento.
BR0016873A (pt) Método e kit para analisar bactérias em uma amostra lìquida
BR0317224A (pt) Processo de detecção de prp (proteìna priÈnio nativa) com uso de um antibiótico dos aminoglicosìdeos
BR9813402A (pt) Preparação de proteìnas, processos diagnóstico para testar esquizofrenia em um indivìduo, e para preparar um reagente para uso no diagnóstico de esquizofrenia, e, kit para uso no diagnóstico de esquizofrenia
BR9507125A (pt) Teste e kit para o diagnóstico de esquizofrenia em um indivíduo
ES2026966T3 (es) Procedimiento para la obtencion de 4-metil-4-fenil-1-penta--nales y su empleo como perfumantes.
FI912286A7 (fi) Immunoreagenssikoostumus, testipakkaus ja nopea menetelmä ihmisen koriongonadotropiinin määrittämiseksi
SE8504666D0 (sv) Forfarande vid protein- eller nukleinsyrablotting
BR9914294A (pt) Dispositivo de medição da atividade enzimática de amostra alimentar sólida, sua utilização e processo de medida da atividade enzimática de um alimento
UA30435A (uk) Спосіб визначення онкологічного маркеру в сироватці крові

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/07/99, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/07/2019